Want to see RZLT full AI Analyst Report?
RZLT Stock Chart & Stats
$3.46
-$0.34(-6.35%)
At close: 4:00 PM EST
$3.46
-$0.34(-6.35%)
Day’s Range― - ―
52-Week Range$1.07 - $11.46
Previous CloseN/A
Volume107.87K
Average Volume (3M)2.05M
Market Cap
$490.13M
Enterprise Value$198.17
Total Cash (Recent Filing)$120.27M
Total Debt (Recent Filing)$1.11M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Sep 10, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding96,292,330
10 Day Avg. Volume1,541,250
30 Day Avg. Volume2,046,012
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.09
Price to Sales (P/S)0.00
P/FCF Ratio-4.91
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.43Price Target Upside143.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$3.22M
Bulls Say, Bears Say
Bulls Say
Positive Phase 3 UpLIFT DataRobust early Phase 3 results in a rare, severe indication materially de-risk the lead program's clinical profile. Durable efficacy signals plus absence of drug-related AEs and high extension enrollment increase the probability of regulatory success and longer-term commercial potential in a niche market.
Constructive FDA EngagementActive, structured dialogue with the FDA reduces regulatory ambiguity and creates a clearer pathway to approval. A formal request for comprehensive submission allows the company to align analyses and endpoints with regulators, improving odds of an approvable dossier over the medium term.
Very Low Leverage On Balance SheetExtremely low debt limits refinancing risk and interest burden, preserving flexibility to fund programs via equity or partnerships. This conservative capital structure supports multi-quarter development programs without immediate debt servicing pressure, aiding strategic optionality.
Bears Say
Pre-revenue Development-stage ProfileLack of product revenue means the business must rely on external financing to fund operations and commercialization. Over the next several months this structural gap preserves high operational risk until regulatory approval and product launch generate sustainable sales.
Accelerating Negative Free Cash FlowRapidly increasing cash burn materially shortens runway absent new financing or partnerships. Persistent negative operating cash flow elevates dilution and funding risk, forcing management to prioritize capital raises which can constrain long-term R&D investment and strategic optionality.
Widening Net Losses And Negative Returns On EquityEscalating losses and deeply negative ROE indicate capital is being consumed rather than generating returns. Over time this erodes shareholder equity and heightens dependency on external capital, limiting the company's ability to build enduring profitability without successful commercialization.
Rezolute News
RZLT FAQ
What was Rezolute, Inc.’s price range in the past 12 months?
Rezolute, Inc. lowest stock price was $1.07 and its highest was $11.46 in the past 12 months.
What is Rezolute, Inc.’s market cap?
Rezolute, Inc.’s market cap is $490.13M.
When is Rezolute, Inc.’s upcoming earnings report date?
Rezolute, Inc.’s upcoming earnings report date is Sep 10, 2026 which is in 49 days.
How were Rezolute, Inc.’s earnings last quarter?
Rezolute, Inc. released its earnings results on May 12, 2026. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.181 by $0.021.
Is Rezolute, Inc. overvalued?
According to Wall Street analysts Rezolute, Inc.’s price is currently Undervalued.
Does Rezolute, Inc. pay dividends?
Rezolute, Inc. does not currently pay dividends.
What is Rezolute, Inc.’s EPS estimate?
Rezolute, Inc.’s EPS estimate is -0.15.
How many shares outstanding does Rezolute, Inc. have?
Rezolute, Inc. has 96,292,330 shares outstanding.
What happened to Rezolute, Inc.’s price movement after its last earnings report?
Rezolute, Inc. reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.181. Following the earnings report the stock price went up 0.909%.
Which hedge fund is a major shareholder of Rezolute, Inc.?
Currently, no hedge funds are holding shares in RZLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rezolute Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.43 (143.60% Upside)
$8.43 (143.60% Upside)
Blogger Sentiment
Neutral
RZLT Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 137.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.89%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
32.43%
Trailing 12-Months
Company Description
Rezolute, Inc.
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
RZLT Stock 12 Month Forecast
Average Price Target
$8.43
▲(143.60% Upside)
Technical Analysis
Ownership Overview
10.87% Insiders
30.62% Mutual Funds
33.54% Other Institutional Investors
14.45% Public Companies and
Individual Investors